Novavax (NVAX) Non-Current Debt (2010 - 2026)

Novavax (NVAX) posted quarterly Non-Current Debt of $291.0 million for Q1 2026, up 19.17% quarter-over-quarter from $244.2 million in Q4 2025.

Novavax (NVAX) Non-Current Debt (2010 - 2026) Analysis & Trends

Novavax's Non-Current Debt history runs 8 years deep, the most recent figure standing at $291.0 million for Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $291.0 million; the TTM figure through Mar 2026 stood at $291.0 million (changed N/A YoY), while the FY2025 annual figure was $244.2 million, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $291.0 million, up from $244.2 million in the prior quarter.
The five-year high for Non-Current Debt was $291.0 million in Q1 2026, with the low at $244.2 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Novavax	1.33 Bn	607.37 Mn	42.45 Mn	291.49 Mn

Download Data